Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In
Trending

Chromium picolinate lowered HbA1c by 0.68% in 12 weeks — but only in a small trial of people with metabolic syndrome

This is one of the first controlled trials to show chromium picolinate can improve long-term blood sugar control in metabolic syndrome, but the modest effect and small sample mean the finding needs replication before it's actionable.

In a 12-week randomized trial of 48 adults with metabolic syndrome, 400 µg/day of chromium picolinate reduced HbA1c — a measure of average blood sugar over the past 2–3 months — by 0.68%. That’s a moderate drop, but the study was small, and other markers like fasting glucose and body weight didn’t budge, so the benefit appears narrow and preliminary.

Where this fits in the evidence

This is among the first studies we've indexed on Chromium for Reduced Hemoglobin A1c — treat it as an early signal until more research accumulates.

The study

The Effect of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers, Tumor Necrosis Factor-α Gene Expression, and DNA Damage in Subjects with Metabolic Syndrome: a Randomized Placebo-Controlled Clinical Trial.

  • Randomized Controlled Trial (RCT)
  • n = 48
  • 2026-03-17
  • Biological trace element research
More on ChromiumMore on Reduced Hemoglobin A1c

This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.

Back to top